A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus who are at high risk of progression to severe disease
2402T1432
Phase 2 other active
Quick answer
A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus who are at high risk of progression to severe disease for Respiratory Syncytial Virus is a Phase 2 program (other) at Shionogi B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Shionogi B.V.
- Indication
- Respiratory Syncytial Virus
- Phase
- Phase 2
- Modality
- other
- Status
- active